Budesonide nanocrystal-loaded hyaluronic acid microparticles for inhalation: In vitro and in vivo evaluation

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Budesonide nanocrystal-loaded hyaluronic acid microparticles for inhalation : In vitro and in vivo evaluation. / Liu, Tingting; Han, Meihua; Tian, Fang; Cun, Dongmei; Rantanen, Jukka; Yang, Mingshi.

In: Carbohydrate Polymers, Vol. 181, 01.02.2018, p. 1143-1152.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Liu, T, Han, M, Tian, F, Cun, D, Rantanen, J & Yang, M 2018, 'Budesonide nanocrystal-loaded hyaluronic acid microparticles for inhalation: In vitro and in vivo evaluation', Carbohydrate Polymers, vol. 181, pp. 1143-1152. https://doi.org/10.1016/j.carbpol.2017.11.018

APA

Liu, T., Han, M., Tian, F., Cun, D., Rantanen, J., & Yang, M. (2018). Budesonide nanocrystal-loaded hyaluronic acid microparticles for inhalation: In vitro and in vivo evaluation. Carbohydrate Polymers, 181, 1143-1152. https://doi.org/10.1016/j.carbpol.2017.11.018

Vancouver

Liu T, Han M, Tian F, Cun D, Rantanen J, Yang M. Budesonide nanocrystal-loaded hyaluronic acid microparticles for inhalation: In vitro and in vivo evaluation. Carbohydrate Polymers. 2018 Feb 1;181:1143-1152. https://doi.org/10.1016/j.carbpol.2017.11.018

Author

Liu, Tingting ; Han, Meihua ; Tian, Fang ; Cun, Dongmei ; Rantanen, Jukka ; Yang, Mingshi. / Budesonide nanocrystal-loaded hyaluronic acid microparticles for inhalation : In vitro and in vivo evaluation. In: Carbohydrate Polymers. 2018 ; Vol. 181. pp. 1143-1152.

Bibtex

@article{dcf63873cb8e46b799507e59d120bc3c,
title = "Budesonide nanocrystal-loaded hyaluronic acid microparticles for inhalation: In vitro and in vivo evaluation",
abstract = "Most inhaled pharmaceutical formulations on the market are intended to exert immediate pharmacological action, even although inhaled sustained-release formulations can be needed to reduce the frequency of dosing. The purpose of this study was to investigate the pulmonary retention and pharmacokinetics of a poorly water-soluble drug after loading its nanocrystal form into inhalable mucoadhesive microparticles composed of hyaluronic acid. It was intended to prolong the pharmacological effect without compromising the dissolution rate of the poorly water-soluble drug. In this study, budesonide, a corticosteroid anti-inflammatory drug, was used as a model poorly water-soluble drug. Submicron budesonide particles were prepared by wet ball milling, and subsequently loaded into hyaluronic acid microparticles by the spray drying process. The ball-milled budesonide particles and the spray-dried microparticles were characterized using dynamic light scattering (DLS), laser diffraction, Scanning electron microscopy (SEM), X-ray powder diffraction (XRD) and differential scanning calorimetry (DSC). Selected formulations were evaluated in terms of their dissolution/release rate, aerosol performance, muco-adhesion and pharmacokinetics in rats. As shown by XRD and DSC analysis, the nanonized budesonide particles in this study were mainly in crystalline form. The dissolution/release study showed that the in vitro release of budesonide from the microparticles was not significantly sustained compared with the dissolution rate of budesonide nanocrystals (BUD-NC). However, the budesonide in the microparticles exhibited prolonged retention on the surface of porcine tracheal tube owing to the muco-adhesion ability of hyaluronic acid. After intratracheal administration to rats, the BUD-NC exhibited a similar pharmacokinetic profile to that of budesonide solution via i.v. injection. In contrast, budesonide loaded in the mucoadhesive microparticles exhibited a significantly prolonged T max and increased bioavailability with the animal model. This study demonstrated that inhaled microparticles composed of hyaluronic acid could produce sustained budesonide pharmacological effects. This can be attributed to the mucoadhesion of the polymer that overcame the mucociliary clearance and, consequently, prolonged the retention of the active substance in the lung without necessarily reducing the in vitro dissolution rate.",
keywords = "Budesonide, Hyaluronic acid, Inhalation, Nanocrystal-embedded microparticles",
author = "Tingting Liu and Meihua Han and Fang Tian and Dongmei Cun and Jukka Rantanen and Mingshi Yang",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.carbpol.2017.11.018",
language = "English",
volume = "181",
pages = "1143--1152",
journal = "Carbohydrate Polymers",
issn = "0144-8617",
publisher = "Pergamon Press",

}

RIS

TY - JOUR

T1 - Budesonide nanocrystal-loaded hyaluronic acid microparticles for inhalation

T2 - In vitro and in vivo evaluation

AU - Liu, Tingting

AU - Han, Meihua

AU - Tian, Fang

AU - Cun, Dongmei

AU - Rantanen, Jukka

AU - Yang, Mingshi

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Most inhaled pharmaceutical formulations on the market are intended to exert immediate pharmacological action, even although inhaled sustained-release formulations can be needed to reduce the frequency of dosing. The purpose of this study was to investigate the pulmonary retention and pharmacokinetics of a poorly water-soluble drug after loading its nanocrystal form into inhalable mucoadhesive microparticles composed of hyaluronic acid. It was intended to prolong the pharmacological effect without compromising the dissolution rate of the poorly water-soluble drug. In this study, budesonide, a corticosteroid anti-inflammatory drug, was used as a model poorly water-soluble drug. Submicron budesonide particles were prepared by wet ball milling, and subsequently loaded into hyaluronic acid microparticles by the spray drying process. The ball-milled budesonide particles and the spray-dried microparticles were characterized using dynamic light scattering (DLS), laser diffraction, Scanning electron microscopy (SEM), X-ray powder diffraction (XRD) and differential scanning calorimetry (DSC). Selected formulations were evaluated in terms of their dissolution/release rate, aerosol performance, muco-adhesion and pharmacokinetics in rats. As shown by XRD and DSC analysis, the nanonized budesonide particles in this study were mainly in crystalline form. The dissolution/release study showed that the in vitro release of budesonide from the microparticles was not significantly sustained compared with the dissolution rate of budesonide nanocrystals (BUD-NC). However, the budesonide in the microparticles exhibited prolonged retention on the surface of porcine tracheal tube owing to the muco-adhesion ability of hyaluronic acid. After intratracheal administration to rats, the BUD-NC exhibited a similar pharmacokinetic profile to that of budesonide solution via i.v. injection. In contrast, budesonide loaded in the mucoadhesive microparticles exhibited a significantly prolonged T max and increased bioavailability with the animal model. This study demonstrated that inhaled microparticles composed of hyaluronic acid could produce sustained budesonide pharmacological effects. This can be attributed to the mucoadhesion of the polymer that overcame the mucociliary clearance and, consequently, prolonged the retention of the active substance in the lung without necessarily reducing the in vitro dissolution rate.

AB - Most inhaled pharmaceutical formulations on the market are intended to exert immediate pharmacological action, even although inhaled sustained-release formulations can be needed to reduce the frequency of dosing. The purpose of this study was to investigate the pulmonary retention and pharmacokinetics of a poorly water-soluble drug after loading its nanocrystal form into inhalable mucoadhesive microparticles composed of hyaluronic acid. It was intended to prolong the pharmacological effect without compromising the dissolution rate of the poorly water-soluble drug. In this study, budesonide, a corticosteroid anti-inflammatory drug, was used as a model poorly water-soluble drug. Submicron budesonide particles were prepared by wet ball milling, and subsequently loaded into hyaluronic acid microparticles by the spray drying process. The ball-milled budesonide particles and the spray-dried microparticles were characterized using dynamic light scattering (DLS), laser diffraction, Scanning electron microscopy (SEM), X-ray powder diffraction (XRD) and differential scanning calorimetry (DSC). Selected formulations were evaluated in terms of their dissolution/release rate, aerosol performance, muco-adhesion and pharmacokinetics in rats. As shown by XRD and DSC analysis, the nanonized budesonide particles in this study were mainly in crystalline form. The dissolution/release study showed that the in vitro release of budesonide from the microparticles was not significantly sustained compared with the dissolution rate of budesonide nanocrystals (BUD-NC). However, the budesonide in the microparticles exhibited prolonged retention on the surface of porcine tracheal tube owing to the muco-adhesion ability of hyaluronic acid. After intratracheal administration to rats, the BUD-NC exhibited a similar pharmacokinetic profile to that of budesonide solution via i.v. injection. In contrast, budesonide loaded in the mucoadhesive microparticles exhibited a significantly prolonged T max and increased bioavailability with the animal model. This study demonstrated that inhaled microparticles composed of hyaluronic acid could produce sustained budesonide pharmacological effects. This can be attributed to the mucoadhesion of the polymer that overcame the mucociliary clearance and, consequently, prolonged the retention of the active substance in the lung without necessarily reducing the in vitro dissolution rate.

KW - Budesonide

KW - Hyaluronic acid

KW - Inhalation

KW - Nanocrystal-embedded microparticles

UR - http://www.scopus.com/inward/record.url?scp=85034788009&partnerID=8YFLogxK

U2 - 10.1016/j.carbpol.2017.11.018

DO - 10.1016/j.carbpol.2017.11.018

M3 - Journal article

C2 - 29253943

AN - SCOPUS:85034788009

VL - 181

SP - 1143

EP - 1152

JO - Carbohydrate Polymers

JF - Carbohydrate Polymers

SN - 0144-8617

ER -

ID: 221825914